ReNeuron is a UK-based stem cell company. Their primary objective is the development of stem cell therapies targeting areas of significant unmet or poorly met medical need. RENE.L’s shares are traded on the London AIM market.
Results from Cytori Therapeutics’ preclinical fat grafting study have been published in the February issue of the Annals of Plastic Surgery. This article, entitled “Supplementation of Fat Grafts with Adipose-Derived Regenerative Cells (ADRCs) Improves Long-Term Graft Retention,” examines the science behind cell-enriched autologous fat grafting and its application to cosmetic and reconstructive surgery.
Cytori Therapeutics received U.S. Patent No. 7,651,684 (the ‘684 patent) which covers the CYTX’s methods for delivering adipose-derived stem and regenerative cell-enriched fat grafts into patients. The ‘684 patent specifically covers cell-enriched fat grafts to treat soft-tissue defects and urinary incontinence. In addition, the ‘684 patent covers methods for delivering cell-enriched fat grafts to a patient’s breast, wrinkles, lips, under the eyes, cheeks, chin, and other parts of the body and broadens current expansive patent portfolio covering adipose-derived cell therapies.
MultiCell Immunotherapeutics specializes in developing primary liver cell immortalization technologies to produce cell-based assay systems for use in drug discovery by leveraging patented technology and expertise to develop therapeutics to treat serious diseases including multiple sclerosis, type-1 diabetes, and infectious disease.
The public offering/ financing further strengthened its’ balance sheet and to complete ongoing Phase II clinical trials:
ASTM announced, 1/14/10 that it intends to offer to sell, subject to market and other conditions, units consisting of shares of its common stock, Class A warrants and Class B warrants, in an underwritten public offering. Read more…
BioTime, Inc (Amex: BTX) develops blood plasma volume expanders and blood replacement solutions for hypothermic (low temperature) surgery, organ preservation solutions and technology for use in surgery, emergency trauma treatment, and other applications. Read more…
Pluristem Therapeutics (NASDAQ: PSTI) is engaged in the production, research and development of placental-derived adherent stromal cells (ASCs). PSTI commercializes non-personalized (allogeneic) cell therapy products for the treatment of various severe degenerative, ischemic and autoimmune disorders. Focus: PSTI develops a pipeline of products that are derived from the human placenta, a non-controversial, non-embryonic, adult stem cell source. These placental adherent stromal cells (ASCs) are expanded in proprietary PluriXTM 3 dimensional bio-reactors; which imitates the natural micro-structure of bone marrow and does not require supplemental growth factors or other exogenous materials. Read more…
Osiris Therapeutics (NASDAQ: OSIR) has focused on the advancement of mesenchymal stem cell (MSC) technologies and is focused on developing and marketing products to treat medical conditions in the inflammatory, orthopedic, and cardiovascular areas. Focus: OSIR’s principal product(s) include Prochymal, for the treatment of steroid refractory Graft versus Host Disease (GvHD), acute GvHD, Crohn’s disease, and acute radiation syndrome; treatment of Type I diabetes mellitus, acute myocardial infarction, chronic obstructive pulmonary disease and Chondrogen, a treatment of osteoarthritis and the reduction of pain in the knee.
There are 337 (276 public and 61 private) lifescience companies presenting starting Monday, 1/11 and running through Thursday, 1/14. Link: JPMHealthcareConference-Agenda1.7
Public company presentations are usually web-cast enabling non-participants to view presentations with breakout sessions immediately following their presentations. These web-casts will be available for 3 months after the conference: https://events.jpmorgan.com/ ; so click on the web-cast link (no need for a user name and password but will be prompted an email address). As related to current economic times, registration of attendees was limited by JP Morgan to a total of about 3,500 versus 6,000 in the past years.
Founder and Director of Research, Henry McCusker enters his tenth (10) year at Scimitar Equity with past experience in sell-side analysis, buy-side management, corporate management and due diligence.